がんにおける二重特異性抗体の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Bispecific Antibodies for Cancer Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET

Market segmentation by target

Comparison by target

CD19/CD3 – Market size and forecast 2018-2023

CD30/CD16A – Market size and forecast 2018-2023

Market opportunity by target

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

Astella Pharma Inc.

Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.

Merus

Regeneron Pharmaceuticals, Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Bispecific antibodies for cancer under development

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Customer landscape

Exhibit 19: Target – Market share 2018-2023 (%)

Exhibit 20: Comparison by target

Exhibit 21: CD19/CD3 – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: CD19/CD3 – Year-over-year growth 2019-2023 (%)

Exhibit 23: CD30/CD16A – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: CD30/CD16A – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by target

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 34: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 36: Key leading countries

Exhibit 37: Market opportunity

Exhibit 38: Impact of drivers and challenges

Exhibit 39: Pipeline for bispecific antibodies for cancer treatment

Exhibit 40: Vendor landscape

Exhibit 41: Landscape disruption

Exhibit 42: Vendors covered

Exhibit 43: Vendor classification

Exhibit 44: Market positioning of vendors

Exhibit 45: Amgen Inc. – Vendor overview

Exhibit 46: Amgen Inc. – Product segments

Exhibit 47: Amgen Inc. – Organizational developments

Exhibit 48: Amgen Inc. – Geographic focus

Exhibit 49: Amgen Inc. – Key offerings

Exhibit 50: Astella Pharma Inc. – Vendor overview

Exhibit 51: Astella Pharma Inc. – Business segments

Exhibit 52: Astella Pharma Inc. – Organizational developments

Exhibit 53: Astella Pharma Inc. – Key offerings

Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. – Vendor overview

Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. – Key offerings

Exhibit 56: Merus – Vendor overview

Exhibit 57: Merus – Product segments

Exhibit 58: Merus – Key offerings

Exhibit 59: Regeneron Pharmaceuticals, Inc. – Vendor overview

Exhibit 60: Regeneron Pharmaceuticals, Inc. – Business segments

Exhibit 61: Regeneron Pharmaceuticals, Inc. – Organizational developments

Exhibit 62: Regeneron Pharmaceuticals, Inc. – Key offerings

Exhibit 63: Validation techniques employed for market sizing


【レポート販売概要】

■ タイトル:がんにおける二重特異性抗体の世界市場2019-2023
■ 英文:Global Bispecific Antibodies for Cancer Market 2019-2023
■ 発行日:2019年4月17日
■ 調査会社:Technavio
■ 商品コード:IRTNTR31178
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。